TAVR is associated with a significantly lower risk of bioprosthetic valve dysfunction than SAVR, according to new data presented at CRT 2025 and simultaneously published in JACC. 

A new spending proposal that would extend government funding for another seven months does not address the Medicare payment cut that went into effect on Jan. 1. More than 100 healthcare groups, including the ACC, STS, SCCT and SCAI, are now voicing their disappointment. 

Researchers presented new two-year data from the SMART trial at CRT 2025 in Washington, D.C. Overall, self-expanding TAVR valves continue to show superior valve performance compared to balloon-expandable valves, and clinical outcomes remain comparable.

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Two separate groups have published new research comparing early AVR with clinical surveillance for the treatment of asymptomatic severe aortic stenosis. Overall, the two groups found, early treatment was associated with multiple benefits—and no added risk of harm.

SCAI President James Hermiller, Jr., MD, explains the need for more innovative radiation protection systems in the cath lab.

The new Self-Centering Guide Catheter was designed to help care teams with the retrograde crossing of the aortic valve during TAVR. Researchers evaluated the safety and effectiveness of the catheter, sharing their experience in JACC: Cardiovascular Interventions.

The biggest differences, researchers noted, were found in the long-term outcomes of low- and intermediate-risk patients.